Delkin Devices Adds VPG400 to BLACK CFexpress 4.0 Line, Offering Industry-Leading Warranty and Standard Capacities
POWAY, CA, UNITED STATES, March 12, 2025 / EINPresswire.com / -- Delkin Devices, a leader in photo and video storage solutions, proudly announces the launch of its latest BLACK CFexpress™ Type B 4.0 memory cards, designed to meet the demanding needs of professional photographers and videographers. Available in 512GB (DCB4BV4512), 1TB (DCB4BV41T), and 2TB (DCB4BV42T) capacities, these cutting-edge cards deliver unparalleled speed, reliability, and durability for high-resolution video and burst photography applications.
Engineered with PCIe technology and a Video Performance Guarantee Profile 4 (VPG400) rating, Delkin's new CFexpress Type B 4.0 cards provide a sustained minimum write speed of 2048MB/s (varies by capacity) but never lower under any circumstances than 400MB/s, making them ideal for capturing RAW 8K, 6K, and 4K video without dropped frames. Featuring maximum burst read speeds of up to 3700MB/s and maximum burst write speeds of up to 3220MB/s (varies by capacity), these cards enable ultra-fast data transfers, reducing downtime and increasing efficiency for creative professionals.
Key Features of Delkin's BLACK CFexpress Type B 4.0 VPG400 Cards:
• World's Best Warranty: Our unmatched 48-hour replacement guarantee (available in the US and Europe; other locations may take longer), combined with exceptional customer service that sets us apart
• Available Capacities: 512GB, 1TB, 2TB
• PCIe Technology & VPG400 Rating for reliable, high-speed video recording
• Serialized Cards for inventory management and verification of authenticity
• Durability: Shockproof, water-resistant, and X-ray proof
• Temperature Range: Operates between 32° and 158°F (0° to 70°C)
'The Video Performance Guarantee (VPG) standard, established by the CompactFlash Association, ensures that media cards can consistently support the high data rates essential for seamless video recording,' said Hiro Ino, President of the CompactFlash Association. 'We are pleased to see Delkin Devices, one of the founding members of the CompactFlash Association, continuing to provide its customers with high-quality products.'
VPG is a critical standard for professional photographers and videographers. It ensures that memory cards sustain the required minimum write speeds to prevent dropped frames, stuttering, or corruption during high-resolution recording. The VPG400 rating guarantees that Delkin's CFexpress Type B 4.0 cards can handle the intensive data throughput required for RAW video capture, making them a reliable choice for high-end cinema and broadcast applications.
Tony Diaz
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
Daversa Earns Great Place To Work Certification™ for Fourth Consecutive Year
NEW YORK--(BUSINESS WIRE)--Daversa is proud to announce its fourth consecutive Great Place To Work® Certification™. With 98% of employees affirming that Daversa is a great place to work - far above the 57% average for U.S. companies - this recognition underscores our commitment to building an exceptional culture. 'This recognition is about the people who make Daversa what it is,' said Founder and CEO, Paul Daversa. 'While the industry transforms monthly through the power of AI, we remain the one firm consistently training the tech industry's most elite recruiters. At Daversa, culture and being a Great Place to Work revolve around obsessing over the experiences we deliver to our people in the office, so they can deliver outsized results for our clients. You can't obsess over clients if you don't first obsess over your people, and having our employees recognize that is something I'm incredibly proud of.' About Daversa Daversa is technology's premier executive search firm that builds the leadership teams for growth and venture-backed companies. Our global footprint spans two continents and eight offices, giving our high-performance teams visibility into the entirety of the market. We are dedicated to developing meaningful relationships with entrepreneurs, executives, and investors across consumer and enterprise businesses. Extraordinary talent is hard to find and even harder to recruit. Focusing our searches on delivering Material Impact executives is what sets us apart, and is what makes Daversa the search partner of choice. About Great Place to Work Certification™ Great Place To Work® Certification™ is the most definitive 'employer-of-choice' recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place To Work-Certified. About Great Place To Work ® As the global authority on workplace culture, Great Place To Work® brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All™ Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified™ or receiving recognition on a coveted Best Workplaces™ List.
Business Wire
4 hours ago
- Business Wire
Xspray Pharma Submits XS003 to the FDA – The Company's Second Product Candidate from the HyNap Platform
STOCKHOLM--(BUSINESS WIRE)-- Xspray Pharma (Nasdaq Stockholm: XSPRAY) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate XS003 (nilotinib) for the treatment of chronic myeloid leukemia (CML). The application is based on successful studies demonstrating bioequivalence with the reference product Tasigna®. XS003 demonstrates the lowest documented food interaction within the nilotinib class and improved dose linearity, which gives physicians greater predictability when adjusting the dose, enabling more consistent exposure and potentially reducing the risk of side effects. Due to XS003's improved food interaction profile, the warning about three hours of fasting, currently included in the reference product's so-called boxed warning, is not expected to apply to XS003. This may simplify treatment and improve adherence. XS003 is an improved formulation of nilotinib (Tasigna®) and developed using the company's proprietary HyNap™ technology. 'Patients with chronic leukemia live not only with their disease—but also with side effects from medications, often related to food interaction and concomitant treatments. Our proprietary HyNap technology addresses these challenges and may help improve treatment outcomes and quality of life for this patient group. Our goal is to develop and commercialize a portfolio of next-generation Protein Kinase Inhibitor products with stable absorption, low variability, and minimal food interaction. With XS003, we now have two product candidates under FDA review with strong clinical potential, addressing a total U.S. market worth USD 2.7 billion,' says Per Andersson, CEO of Xspray Pharma. Data from registration studies demonstrate bioequivalence with the reference product, despite XS003 being administered at less than half the dose of the reference product. In addition, the studies confirm clearly improved dose linearity, which may provide physicians with better predictability when adjusting doses, and thereby a greater ability to achieve improved treatment outcomes. The uptake of XS003 is only slightly affected when taken with food, while the reference product is significantly affected as reflected in their label (28% vs. 82%). This may indicate improved control and a lower risk of side effects when taken with food. Xspray expects the FDA to initiate its review within 60 days, with a regulatory decision anticipated approximately eight months thereafter. Global 2024 nilotinib sales reached USD 1.67 billion in 2024, of which USD 850 million came from the U.S. About Xspray Pharma Xspray Pharma AB (publ) is a pharmaceutical company focused on the development of improved PKIs for cancer treatment, leveraging its proprietary HyNap™ technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Xspray Pharma's shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). For more information about Xspray Pharma AB and its innovative approach to cancer treatment, please visit
Business Wire
5 hours ago
- Business Wire
Pearl Expands AI Integration with Curve Dental to Include Practice Intelligence
LOS ANGELES--(BUSINESS WIRE)-- Pearl, the global leader in dental AI solutions, and Curve Dental ®, the premier provider of cloud-based dental practice management software, today announced the expansion of their integration to include Pearl's Practice Intelligence ®. This AI-powered analytics solution helps dental practices surface opportunities for improved care, increased production, and stronger operational efficiency. By integrating Practice Intelligence directly into Curve SuperHero, dental organizations can now move from diagnosis to action with greater clarity. Practices gain access to smarter decision-making tools that enhance every stage of the patient journey. Share This expanded partnership builds on the successful integration of Pearl's Second Opinion® radiologic AI capabilities within Curve Dental's SuperHero™ platform. With the addition of Practice Intelligence, Curve Dental's 80,000+ users across the United States and Canada now have seamless access to both real-time radiologic support and comprehensive AI-driven practice analytics within a single, unified interface. 'Curve has always been committed to delivering the tools our customers need to grow smarter, more successful practices,' said Jana Macon, Curve Dental President. 'By expanding our relationship with Pearl to include Practice Intelligence, we're empowering our users with instant, actionable insights that help them make informed clinical and business decisions every day. It's another step forward in Curve's mission to provide future-ready solutions for today's dental teams.' Pearl's Practice Intelligence uses AI to continuously monitor radiographic data, treatment plans, and patient records. The platform identifies patterns and opportunities to: Uncover undiagnosed and untreated patient conditions Surface provider and location-level performance metrics Standardize clinical output across providers Optimize scheduling, recall, and case acceptance efforts Increase production per patient By integrating Practice Intelligence directly into Curve SuperHero, dental organizations can now move from diagnosis to action with greater clarity. Practices gain access to smarter decision-making tools that enhance every stage of the patient journey and overall business operations. 'We're excited to deepen our collaboration with Curve by bringing Practice Intelligence to their community,' said Ophir Tanz, CEO of Pearl. 'This integration delivers on the vision of intelligent practice management, where diagnostics, analytics, and decision support work together to help dental teams raise the standard of care and performance across the board.' Want to supercharge Curve with Pearl's Practice Intelligence ®? Click here to learn more. About Pearl Pearl is an AI-driven company committed to enhancing patient care in dentistry. Founded in 2019 by a team with decades of experience developing successful, enterprise-grade computer vision solutions, Pearl introduced the first-ever FDA-cleared AI capable of reading and instantly identifying diseases in dental x-rays. With regulatory clearance in 120 countries, Pearl's AI assists dentists in making precise clinical decisions and effectively communicating with patients, thereby transforming the dental care experience worldwide. As dentistry's global AI leader, Pearl is committed to the ongoing innovation of robust, accessible AI tools that improve patient health outcomes and build greater trust in dental medicine. To request a demo, please visit About Curve Dental Curve Dental provides the leading cloud-based practice management software for over 80,000 dental professionals across the United States and Canada. From the start, Curve Dental has been singularly focused on the dental industry and is committed to delivering the best all-in-one dental practice management and patient engagement software for practices of all sizes. The company is privately-held, with offices in Provo, Utah; Atlanta, Georgia; Calgary, Alberta; and Aberdeen, Scotland. Visit or call 1-888-910-HERO for more information.
